Drugs / silybin phosphatidylcholine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02633696 | Oct → Nov 2013 | — | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | silybin phosphatidylcholine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02633696 ↗ |
| Route | Oral | “9 capsules of 40 mg of sylibin each one (360 mg in total) orally” NCT02633696 ↗ |